title: Radionuclide therapy via SSTR: future aspects from experimental animal studies.
abstract: There is need for better therapeutic options for neuroendocrine tumours. The aim of this review was to summarize results of experimental animal studies and raise ideas for future radionuclide therapy based on high expression of somatostatin (SS) receptors by many neuroendocrine tumours. In summary, one of the major options is individualized treatment for each patient, including choice of SS analogues, radionuclides and treatment schedules. Other options are methods to increase the treatment effect on tumour tissue (increasing tumour uptake and retention by upregulation of receptor expression and avoiding saturation of receptor binding), methods to increase the tumour tissue response (by choice of radionuclides, SS analogues or combined therapies), and methods to reduce side effects (diminished uptake and retention in critical organs and reduced normal tissue response). Furthermore, combination therapy with other radiopharmaceuticals, cytotoxic drugs or radiosensitizers can be considered to enhance the effects of radiolabelled SS analogues.
authors.affiliation: Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Centre, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. eva.forssell_aronsson@radfys.gu.se
authors.forename: Eva
authors.initials: E
authors.lastname: Forssell-Aronsson
authors.forename: Johan
authors.initials: J
authors.lastname: Spetz
authors.forename: Håkan
authors.initials: H
authors.lastname: Ahlman
mesh_terms: D000818:Animals; D018278:Carcinoma, Neuroendocrine / Q000628:therapy*; D004195:Disease Models, Animal; D011868:Radioisotopes / Q000494:pharmacology*; D019275:Radiopharmaceuticals / Q000494:pharmacology*
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals